Sofosbuvir / Velpatasvir / Voxilaprevir

Pravastatin

Use with caution.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Sofosbuvir / Velpatasvir / Voxilaprevir can inhibit OATP1B1 and increase the plasma concentration of Pravastatin.

Sofosbuvir / Velpatasvir / Voxilaprevir

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Pravastatin

Pharmacodynamic effects

Possible increase of adverse effects.

Increased risk of myopathy and rhabdomyolysis.

Recommendations

Use this combination with caution.

We do not recommend more than 40 mg per day.

Monitor for adverse effects.

Alternative solution(s)

Monitor

Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.

Tests

CK

Lipidic profile

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
AUC
Cmax
Sofosbuvir / Velpatasvir / Voxilaprevir
3379
19
-
400/100/200 mg
QD
 
 
Pravastatin
3379
19
-
40 mg
x 1
+ 116% (2.1x)
+ 89% (1.9x)
Comment

Reference
  • 3379
    Sofosbuvir/Velpatasvir/Voxilaprevir (VOSEVI), Gilead, Ontario, Canada, 28 janvier 2020.